Wambolt & Associates LLC Has $1.37 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Wambolt & Associates LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 33.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,807 shares of the company’s stock after purchasing an additional 449 shares during the quarter. Wambolt & Associates LLC’s holdings in Eli Lilly and Company were worth $1,374,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $5,992,890,000. International Assets Investment Management LLC raised its position in Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after purchasing an additional 7,330,815 shares in the last quarter. Sapient Capital LLC acquired a new position in Eli Lilly and Company in the fourth quarter worth about $682,139,000. Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares during the period. Finally, Comerica Bank acquired a new stake in Eli Lilly and Company during the third quarter valued at approximately $345,781,000. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 8,848 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total value of $8,098,662.88. Following the completion of the sale, the insider now directly owns 97,299,772 shares of the company’s stock, valued at approximately $89,059,454,309.32. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 8,848 shares of the company’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the completion of the sale, the insider now owns 97,299,772 shares of the company’s stock, valued at approximately $89,059,454,309.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 858,742 shares of company stock valued at $735,573,781. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Up 1.8 %

Shares of NYSE LLY opened at $914.57 on Friday. Eli Lilly and Company has a 1 year low of $434.34 and a 1 year high of $918.50. The firm’s 50-day moving average is $831.69 and its 200-day moving average is $751.25. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The firm has a market capitalization of $869.22 billion, a PE ratio of 134.69, a price-to-earnings-growth ratio of 1.99 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same period last year, the firm earned $1.62 earnings per share. Equities analysts expect that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LLY. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, July 1st. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Argus increased their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. The Goldman Sachs Group upped their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $1,023.00 target price on shares of Eli Lilly and Company in a research note on Friday. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $816.78.

Get Our Latest Stock Analysis on LLY

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.